2.94

6.07% -0.19

After Hours: 2.99 0.05 +1.70%

Abcellera Biologics Inc (ABCL)

Overview News Price History Option Chain Financials Why ABCL Down? Discussions Forecast

Abcellera Biologics Inc stock is traded at $2.94, with a volume of 3.79M. It is down -6.07% in the last 24 hours and down -34.96% over the past month. AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

Previous Close:

$3.13

Open:

$3.2

24h Volume:

3.79M

Relative Volume:

0.86

Market Cap:

$880.05M

Revenue:

$38.03M

Net Income/Loss:

$-146.40M

P/E Ratio:

-5.6538

EPS:

-0.52

Net Cash Flow:

$-121.38M

1W Performance:

+5.76%

1M Performance:

-34.96%

6M Performance:

-31.15%

1Y Performance:

-5.16%

1-Day Range:

$2.93

$3.20

1-Week Range:

$2.8801

$3.28

52-Week Range:

$1.8906

$6.515

Abcellera Biologics Inc Stock (ABCL) Company Profile

Name

Abcellera Biologics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

(604) 559-9005

Address

150 W 4TH AVENUE, VANCOUVER

Employee

596

Twitter

Next Earnings Date

2024-11-18

Latest SEC Filings

ABCL's Discussions on Twitter

Compare ABCL vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ABCL Abcellera Biologics Inc	2.94	936.92M	38.03M	-146.40M	-121.38M	-0.52
VRTX Vertex Pharmaceuticals Inc	465.02	117.03B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	783.65	82.35B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	833.54	51.64B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	308.48	42.58B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	346.42	38.87B	4.98B	69.60M	525.67M	0.5198

Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-07-25	Downgrade	Leerink Partners	Outperform → Market Perform
Jul-07-25	Resumed	Leerink Partners	Outperform
Aug-20-24	Downgrade	The Benchmark Company	Buy → Hold
Feb-22-24	Upgrade	The Benchmark Company	Hold → Buy
Dec-05-23	Initiated	KeyBanc Capital Markets	Overweight
Nov-06-23	Downgrade	The Benchmark Company	Buy → Hold
Oct-13-23	Resumed	Piper Sandler	Overweight
Feb-28-23	Initiated	Cowen	Outperform
Dec-15-22	Initiated	Goldman	Buy
Nov-16-22	Initiated	Truist	Buy
Dec-21-21	Initiated	The Benchmark Company	Buy
Nov-19-21	Initiated	Piper Sandler	Overweight
Jan-05-21	Initiated	BMO Capital Markets	Outperform
Jan-05-21	Initiated	Berenberg	Buy
Jan-05-21	Initiated	Credit Suisse	Outperform
Jan-05-21	Initiated	SVB Leerink	Outperform
Jan-05-21	Initiated	Stifel	Buy

View All

Abcellera Biologics Inc Stock (ABCL) Latest News

06:39 AM

State of Michigan Retirement System Acquires 350,775 Shares of AbCellera Biologics Inc. $ABCL - MarketBeat

06:39 AM

03:00 AM

Is AbCellera’s Biotech Platform Setting New Standards for Pharmaceutical Innovation - Kalkine Media

03:00 AM

Feb 11, 2026

Painful Week for Individual Investors Invested in AbCellera Biologics Inc. (NASDAQ:ABCL) After 10% Drop, Institutions Also Suffered Losses - 富途牛牛

Feb 11, 2026

Travel Stocks: Is Lifeway Foods Inc forming a double bottom2025 Analyst Calls & Daily Chart Pattern Signals - baoquankhu1.vn

Feb 11, 2026

AbCellera to Present at Upcoming Investor Conferences in March and April 2026 - Investing News Network

Feb 11, 2026

Feb 05, 2026

Is AbCellera (ABCL) Trading Its Platform Identity For Higher-Stakes Clinical Ambitions? - Sahm

Feb 05, 2026

Short sales on the TSX: What bearish investors are betting against - The Globe and Mail

Feb 05, 2026

Feb 03, 2026

AbCellera’s ABCL635 Phase 2 Start Highlights Menopause Focus And Valuation Gap - Yahoo Finance

Jan 31, 2026

Jan 30, 2026

AbCellera Biologics (ABCL) Valuation Check After Mixed Long Term Shareholder Returns - Yahoo Finance

Jan 30, 2026

AbCellera Advances ABCL635 Menopause Candidate As Shares Trade Below Targets - Sahm

Jan 30, 2026

Reassessing AbCellera Biologics (ABCL) After A Sharp 16.8% Weekly Share Price Drop - Yahoo Finance

Jan 30, 2026

Jan 29, 2026

What Does Wall Street Think About AbCellera Biologics Inc. (ABCL)? - Insider Monkey

Jan 29, 2026

Jan 26, 2026

Exit Recap: Why is AbCellera Biologics Inc stock going downJuly 2025 Sector Moves & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn

Jan 26, 2026

Can AbCellera Biologics Inc disrupt its industry2025 Winners & Losers & Free High Return Stock Watch Alerts - baoquankhu1.vn

Jan 26, 2026

Jan 25, 2026

Strategic Moves Shape ABCL’s Market Position - StocksToTrade

Jan 25, 2026

AbCellera’s Market Moves: Key Developments - timothysykes.com

Jan 25, 2026

Jan 24, 2026

AbCellera Biologics Inc. (NASDAQ:ABCL) Given Average Rating of "Hold" by Brokerages - MarketBeat

Jan 24, 2026

Jan 23, 2026

AbCellera Biologics (NASDAQ:ABCL) Trading Down 6.1%Here's Why - MarketBeat

Jan 23, 2026

Is AbCellera Biologics Inc a top pick in the sectorPortfolio Value Summary & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn

Jan 23, 2026